Collectively, these findings suggest that LSD1 inhibition by SP-2577 treatment reduced the targeted therapy-induced interaction of LSD1-CoREST2-STAT3 and subsequent lineage plasticity in BRAFV600E CRC. This evidence concerns the gene STAT3 and colorectal carcinoma.